Amyotrophic Lateral Sclerosis (ALS)



A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: CK-2127107;   Drug: Placebo
Sponsors:   Cytokinetics;   Astellas Pharma Inc
Not yet recruiting - verified May 2017


Virtual Task in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Acquisition on TouchScreen;   Device: Acquisition on Kinect;   Device: Acquisition on LeapMotion;   Device: Acquisition on TouchScreen Control Group;   Device: Acquisition on Kinect Control Group;   Device: Acquisition on LeapMotion Control Group
Sponsor:   University of Sao Paulo
Completed - verified April 2017


Trial of Amivita in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: Amivita
Sponsors:   Wujin People's Hospital;   Nanjing 1718 Biotech Co. Ltd
Recruiting - verified April 2017


Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: RNS60;   Drug: Placebo
Sponsor:   Revalesio Corporation
Not yet recruiting - verified April 2017


Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis


Condition:   Sporadic Amyotrophic Lateral Sclerosis
Intervention:   Other: Skin Biopsy
Sponsor:   University Hospital, Angers
Not yet recruiting - verified November 2016


Therapeutic Treatment of Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: Biological: Cell-based therapy
Sponsor:   University of Warmia and Mazury
Enrolling by invitation - verified August 2016


Amyotrophic Lateral Sclerosis: a New Paradigm


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: study ALS patients
Sponsor:   Conde, Bebiana, M.D.
Recruiting - verified March 2017


Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Micro Mouth Pressure Meter;   Device: Iowa Oral Performance Instrument;   Device: Electrical Impedance Myography;   Drug: Capsaicin;   Procedure: Videofluoroscopic Swallowing Study;   Procedure: Pulmonary Function Testing;   Other: Swallowing Related Quality of Life Questionnaire;   Other: Functional Oral Intake Scale;   Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised;   Other: Eating Assessment Tool-10;   Other: Communicative Effectiveness Survey;   Other: The Center for Neurologic Studies Bulbar Function Scale
Sponsor:   University of Florida
Recruiting - verified March 2017


Muscular Biomarkers in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: Samples
Sponsor:   University Hospital, Tours
Recruiting - verified October 2016


Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Device: Faros Sensor (FS) and LifeInsight Hub;   Device: Fast Fix electrode patch;   Procedure: Quantitative Measure of Speech (Core Phase Only)
Sponsors:   GlaxoSmithKline;   McLaren Applied Technologies
Active, not recruiting - verified May 2017


HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Darunavir;   Drug: Ritonavir;   Drug: Raltegravir;   Drug: Zidovudine
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Enrolling by invitation - verified February 1, 2017


Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Biological: Stem Cell
Sponsor:   Neurogen Brain and Spine Institute
Completed - verified September 2016


Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Placebo (for MN-166);   Drug: MN-166
Sponsors:   MediciNova;   Carolinas Healthcare System
Active, not recruiting - verified September 2016


Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Placebo;   Drug: 1.0 MIU IL-2 per day;   Drug: 2.0 MIU IL-2 per day
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Completed - verified May 2016


Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Genetic: VM202
Sponsor:   ViroMed Co., Ltd. dba VM BioPharma
Active, not recruiting - verified October 2016


Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Other: MRI
Sponsor:   University of Michigan
Active, not recruiting - verified April 2017


Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Other: MRI;   Other: Clinical Exam
Sponsor:   University of Michigan
Recruiting - verified April 2017


A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: Repository corticotropin injection
Sponsor:   Mallinckrodt
Completed - verified November 2016


Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Rasagiline;   Drug: Placebo
Sponsor:   University of Ulm
Completed - verified October 2016


Gilenya in Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Gilenya;   Other: Placebo
Sponsors:   Massachusetts General Hospital;   ALS Therapy Development Institute
Completed - verified June 2016


The National Amyotrophic Lateral Sclerosis Registry


Condition:   Amyotrophic Lateral Sclerosis
Intervention:  
Sponsors:   Centers for Disease Control and Prevention;   VA Office of Research and Development;   Centers for Medicare and Medicaid Services
Recruiting - verified July 2015


Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Ozanezumab;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)


Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Procedure: Laminectomy and bone marrow stem cells transplantation;   Procedure: Intrathecal infusion of autologous bone marrow stem cells;   Procedure: Intrathecal infusion of placebo (saline solution).
Sponsors:   Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia;   Instituto de Salud Carlos III;   Hospital Universitario Virgen de la Arrixaca;   Hospital General Universitario Morales Meseguer;   Fundación Diógenes
Completed - verified November 2015


Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)


Condition:   Amyotrophic Lateral Sclerosis (ALS)
Interventions:   Drug: MCI-186;   Drug: Placebo of MCI-186
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed - verified April 2017


The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study


Condition:   Amyotrophic Lateral Sclerosis
Intervention:  
Sponsors:   University of Miami;   ALS Association
Recruiting - verified April 2017

Refine Your Search Advanced Search